"I have portfolio of 9 bio tech stocks all under $3 and all were up except this one. "
You and your cronies post the same drivel over and over. We need to welcome another one of the sock puppet gang ,ustapen ! We'll throw you on the junk heap with atabank, zeldoni etc.
Aw, you Ninja traders are still using the old play book lines from 15 years ago. Should we tell the board about the history of you Ninja traders ?
You said 'because as much as is condition is sever the chance for him to receive the real drug is decrease'. I disagree with that. No one knows who will receive the treatment or the placebo. It would be unethical to pick and chose who got what. They need a mix across the board to come to any conclusion regarding results.
Don't respond to him and all the other group shorts working this board. They are begging you to reply , then they get paid. Better to let them sink in their own quicksand . This is a thinly traded issue . My guess, they got stuck on a high volume day (thinking momo was on their side) . Volume disappeared and now they are attempting to unwind their position.
It's okay to let them blather on. Let them waste their time , not yours.
Remember , don't keep their subject line going or respond too much to them. They get paid to post, paid when anyone replies !
He is considered early stage (think they were only accepting early stage in the trials). Don't know what his scores were on the pre enrollment testing prior to being accepted. I can tell you that in the last six months things are declining ..... has trouble with his hands, extremely tired , and was just fitted for leg braces .
His next appointment is Sept 10th . I will keep you all posted. I think he will know fairly early if he got the placebo or real treatment.
Have a good day.
Gee, look at all the various short clowns working this board. Typical case of attempting to work down a thinly traded issue. I can think of 1,000 other issues where they'd have a better short thesis and possibility to score dollars. But, FUD is their game with small developing bios.
Careful, stealing shares alert !!!!
My friend had his final appointment last Monday to meet with the team of Drs involved in the clinical trial. Vry impressed with all involved. He is in UMass this a.m. ..... they are harvesting his stem cells ! Fingers crossed .
Though it's a double blind trial I am sure that once his cells are reintroduced it won't take long to know whether or not he got the real deal. Think his next appointment for that procedure is early September. I'll keep the board updated as I hear any information.
Have a nice day all
Here's who really can't be trusted ! (you and your sock puppet tag team group) . Too funny, thanks for the laugh !
zeldoni • Aug 7, 2015 12:51 PM Flag
I agree, Roth can't be trusted as history is very clear about their intentions.
They say something and it is never happens that way. Then they suddenly change their price target and life goes on . They should be shut down long time ago.
atbaank • Aug 7, 2015 1:08 PM
Exactly. Roth Capitol was pumping many stocks in biotech area in the past and always it was felt it was not right. Same it was here when Roth pumped stock in decline recently with price of $18? What a clear misleading manipulating information. Why stock didn't go higher ? Because nobody trust Roth Capitol, people know their shady record about PT they issue.
CPXX is very risky stock to invest and it is not worth the risk. They have nothing what would make this company worth to invest in as per now!
Found this from July 27th :
Roth Capital reiterated a Buy rating on Celator Pharmaceuticals (NASDAQ: CPXX), and raised the price target to $18.00 (from $15.00). Analyst Joseph Pantginis believes that there is disconnect in regards to share price and fundamental opportunity for Vyxeos.
Pantginis commented, "We believe a significant disconnect exists with regard to CPXX' share price and the fundamental opportunity for Vyxeos. We believe Vyxeos represents the first potential meaningful improvement to treating AML in decades, and believe clinical data to date support our thesis. Reiterate Buy and target upped to $18 from $15 as we introduce our market model for the potential first indication."
Pantginis also added, "Celator has reached the end of a long wait and has set the stage for what we project will be a positive outcome to the Phase III sAML program with Vyxeos (CPX-351) in 1Q16. We are introducing our market model for the initial indication as well as our updated clinical NPV model which drives our new price target of $18 (from $15)."
Sorry you are forgetful. That's a sad claim to make and admit.
I read guys like you. You clearly signaled exactly the type of person you are. Look at your posting history.
Glad you are all in cash. We can now skip all the drivel you post.
Have a good day.
Glad you are in all cash.
I've heard and seen it all in my 35+ years in the market. I have never been in all cash and it's worked out well for me. My best investments always happened when guys like you panicked and dumped out and dragged your feet getting back in out of fear.
I'm sticking with my investments. Thanks anyway.
Ah, all the very familiar basher names are showing up .....
derrick AKA michelle
They will try to steal your shares. Careful longs.
Nice ! And I decided to sleep in this morning . Maybe I'll do that more often.
Good day to all
Hello boys. Haven't seen you work over a boar in ages.
atabank, zeldoni, floridahockey
You can't make it big on a thinly traded issue. Time for the group to move on. Oh, and take michelle with you